繁体
简体
Company news IP granted Publications
2026-07-20
Risen Pharma Announces First Patient Dosed in Phase 2 Clinical Trial of RP902 for Mild Cognitive Impairment Due to Alzheimer’s Disease
Details
Year:
All 2026 2025 2024 2023 2022 2021 2020
Shanghai Zhangjiang R&D Center.
Suzhou Industrial Park R&D Center.
Jiangsu Xuzhou R&D Center
send mail
Copyright 2022 Risen(Shanghai) Pharma Tech Co., Ltd. All Rights Reserved 沪ICP备16020731号-1 Design by：yushangweb